Heterogeneity in adverse events associated with lumateperone: a study on potential subgroup-specific differences

Area of Science:

• Pharmacovigilance
• Clinical Pharmacology

Background:

• Lumateperone is a novel atypical antipsychotic for schizophrenia and bipolar disorder.
• Previous studies identified over 100 adverse events (AEs) but subgroup differences were unclear.

Purpose of the Study:

• To comprehensively evaluate lumateperone's AE profile using FDA Adverse Event Reporting System (FAERS) data.
• To identify potential differences in AEs across patient subgroups.

Main Methods:

• Analysis of 1762 FAERS reports and 5074 AEs associated with lumateperone.
• Utilized ROR algorithm and Fisher's exact test with Bonferroni correction for signal detection.
• Subgroup analyses included report year, reporter type, sex, age, outcome, indication, and concomitant drugs.

Main Results:

• Females reported a higher frequency of nervous system disorders.
• Tardive dyskinesia led to more serious consequences.
• Bipolar disorder patients reported more nervous system disorders; schizophrenia patients reported more psychiatric disorders.

Conclusions:

• Preliminary findings suggest potential differences in lumateperone AEs based on sex, outcome, and indication.
• Further confirmatory studies are needed to validate these subgroup differences.